万邦德：“一种二硫环肽化合物及其制备方法和应用”取得专利证书

Group 1 - The core point of the article is that Wanbangde Pharmaceutical Holdings Group Co., Ltd. has received a patent for a new compound and its preparation method, which may enhance its competitive edge in the pharmaceutical industry [2] - Wanbangde's revenue composition for the year 2024 is as follows: 48.76% from pharmaceutical manufacturing, 32.21% from specialized equipment manufacturing and services, 15.41% from pharmaceutical distribution, and 3.62% from other industries [2]